Vectura and UCB form inflammatory disease collaboration

Published: 30-Sep-2013
Research & Development Pharmaceutical

Will focus on bringing to clinical proof-of-concept a UCB-generated biological therapy targeting a key molecule in the immune system


Chippenham, Wiltshire, UK-based medical technology group Vectura has entered into a collaboration with Belgium-based pharma firm UCB to develop an innovative biologic immunomodulatory product in the area of inflammatory respiratory disease.

No financial details have been released.

The collaboration aims to leverage Vectura’s expertise in the pharmaceutical and clinical/regulatory development of inhaled therapeutics with UCB’s biologics and immunology assets.

Vectura has seven products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies.

The collaboration will focus on bringing to clinical proof-of-concept a UCB-generated biological therapy targeting a key molecule in the immune system.

This is a significant collaboration that combines the innovative and development strengths of Vectura and UCB

The companies will jointly manage the programme, with UCB focusing on bioprocess and preclinical development and Vectura taking responsibility for the pharmaceutical and clinical development of the dry powder product through to clinical proof-of-concept.

Chris Blackwell, Chief Executive of Vectura said: 'Vectura’s growth depends in large part on its ability to remain at the cutting edge of development of products targeting airways-related disease.

'This is a significant collaboration that combines the innovative and development strengths of Vectura and UCB, and mitigates the cost and risk of development of novel products, in line with our stated strategy.'

Mark Bodmer, Vice President UCB New Medicines, Head of Immunology, added: 'There is significant unmet need that is driven by disorders of the immune system. By bringing together UCB’s biologics and immunology expertise and Vectura’s disease know-how and technologies, we hope to bring relief to people suffering from these severe illnesses worldwide.'

  • Companies:
  • Vectura Group
  • UCB
See more

You may also like

Drug Delivery

Optimising dry powder inhaler programmes through formulation

Read more
The use of dry powder formulations originally focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) because pulmonary administration of the active pharmaceutical ingredient (API) provides direct and rapid action. However, direct delivery to the lung is also a quick and efficient way of administering non-respiratory drugs systemically without have to wait for them to be absorbed through the gut

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  3. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  5. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Drug Delivery

Optimising dry powder inhaler programmes through formulation

The use of dry powder formulations originally focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) because pulmonary administration of the active pharmaceutical ingredient (API) provides direct and rapid action. However, direct delivery to the lung is also a quick and efficient way of administering non-respiratory drugs systemically without have to wait for them to be absorbed through the gut
Manufacturing

Vectura signs agreement with Kinaset to develop asthma treatment

Kinaset may pursue VR588 products in other indications and Vectura will be entitled to milestones and royalties on future products
Ingredients

Therapeutics: rozanolixizumab for primary immune thrombocytopenia

Primary immune thrombocytopenia (ITP) is a rare acquired autoimmune disorder. Most patients have pathogenic IgG autoantibodies that target platelets and their precursor megakaryocytes
Research & Development

Vectura partners with Monash University on inhaled oxytocin

The inhalation formula will be used instead of the current injection method
Ingredients

Therapeutics: dapirolizumab for systemic lupus erythematosus

Although there have been some advances in recent years, systemic lupus erythematosus (SLE) remains a significant unmet medical need
Packaging

Pharmapack Europe 2019 reveals winners

Award winners have been selected for innovation in delivery, dosage and packaging of pharmaceutical products
Pharmaceutical

Increasing competition in the psoriasis market

UCB, a global biopharmaceutical company, has potential to compete in the psoriasis market with Cimzia FDA approval, says GlobalData
Subscribe now